Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. - Wikidata - wikimedia - TriplyDB

Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.

Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.

http://www.wikidata.org/entity/Q34308674

about

Spinal cord tumours: advances in genetics and their implications for treatment Oligodendroglioma: pathology, molecular mechanisms and markers Telomere maintenance and the etiology of adult glioma Genetic Inactivation of ATRX Leads to a Decrease in the Amount of Telomeric Cohesin and Level of Telomere Transcription in Human Glioma Cells The somatic genomic landscape of glioblastoma Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification Decreased expression of the chromatin remodeler ATRX associates with melanoma progression The epidemiology of glioma in adults: a "state of the science" review Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors The genetic landscape of anaplastic astrocytoma.ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples.Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy.TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.A Molecular Predictor Reassesses Classification of Human Grade II/III Gliomas Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas.Clinicopathologic features of pediatric oligodendrogliomas: a series of 50 patients The future of high-grade glioma: Where we are and where are we going.BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.CHK1-driven histone H3.3 serine 31 phosphorylation is important for chromatin maintenance and cell survival in human ALT cancer cells.Protein domain-level landscape of cancer-type-specific somatic mutations.IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas.Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma.Isocitrate dehydrogenase mutations in gliomas Co-expression of mitosis-regulating genes contributes to malignant progression and prognosis in oligodendrogliomas.IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma.IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas What do we know about IDH1/2 mutations so far, and how do we use it?Atrx deficiency induces telomere dysfunction, endocrine defects, and reduced life span.Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas Loss of ATRX and DAXX expression identifies poor prognosis for smooth muscle tumours of uncertain malignant potential and early stage uterine leiomyosarcoma Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas.Is glioblastoma an epigenetic malignancy?Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas.Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.Chromatin remodeling defects in pediatric and young adult glioblastoma: a tale of a variant histone 3 tail.

P2860

Q26851596-59FD8105-4468-4CC6-B283-30ADACFED85E Q27002448-145196DF-9E98-42B5-A3E5-56BDE3ABA03F Q28084275-B58243F7-BDDB-43C9-88B2-DBCE4686F383 Q28118722-E4B04C8F-29C2-43AF-A0D0-4CCDD4C24035 Q28300185-D9F2A0B1-53D4-4CE5-920D-002F7E37C91F Q28383205-72116F00-B8CD-420D-ADC7-03707B5C7A5D Q28385936-F084BF0F-4151-444E-B035-85BB85E34CA5 Q28387839-1BB9E3B8-67BC-4614-AB0E-5491D9D869A5 Q30370204-831F5A87-4D14-4E29-AAC0-2BDF48A0605D Q33688888-21F06B82-79AC-4D39-BCE2-B727B3194698 Q33757037-167FB599-290D-41D7-ABE8-76DB3721164C Q33804713-E44D0EC2-7D3B-460F-BE9C-630CA53AE76E Q34342958-5EF9AA8B-6AB0-4A2C-909F-A8E202EE0C55 Q34499685-B6F4D7B6-5B7B-428A-815E-14C74125E049 Q34785423-E7FF713E-D908-4E96-B0FD-7298292B9BB1 Q34998940-757D81C6-B710-484F-8C35-DA6D491C1088 Q35067733-3C49161A-6670-47DD-A554-6519F854D3FB Q35114090-B27C9899-48E2-4D86-A1CF-07D8B1CCA06E Q35168770-47BA09AC-0DEB-4467-9EDF-9F0070ABC6BC Q35171587-6B55AC8A-FF5F-4BB8-974A-1F07086C6CF7 Q35203134-FB125AF5-9B62-4B1B-8067-A35B4B9D0F70 Q35204658-8C671463-98C7-482D-AF07-AC04BD9695BF Q35418206-F9A359A7-9A55-461D-BE18-0232DD749CD0 Q35911314-C17591AF-5E5B-4A7D-BB69-35F6549F794B Q36082467-3C1BC054-D316-4BA4-81D0-F5C4EB85936C Q36367409-B2E3694F-3BBD-4F53-B236-37E47D57999B Q36546013-9A332869-CE18-47E4-81C5-822149E980F7 Q36557547-4E4963C2-4636-44A5-9EA1-ED80267297B1 Q36557573-9F721B14-CD81-4A68-B774-868266CF3A63 Q36737930-B9AA0868-14D8-4977-9FFB-9321D939F583 Q36780903-3861C174-7438-49CF-9C21-B60774A31543 Q36788229-E097D323-31E9-4A38-9AB3-64092D3257D0 Q36793436-38E2E06C-BC2B-47C3-866B-325CC02ED5F1 Q36865995-577DF5A3-67C1-46CC-9901-1773178C00A4 Q36873846-49E9907F-369D-4E1B-8EFA-CADCF39B1423 Q36981245-B34BF55E-94F1-4619-BE5B-D6BD4349DB2A Q37226526-4519AC38-8BA0-4AA5-811E-6E5C3782AA2F Q37580501-A0220481-D34B-4ED3-B309-D57124D4D5D8 Q37665574-19F80F4E-2B10-4D22-9BC0-9FC27E64B525 Q38083799-99646A35-C759-4F4E-B418-7AE92AAFC86D

P2860

Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.

http://www.wikidata.org/entity/Q34308674

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Whole-exome sequencing identif ...... rminant in lower-grade glioma.

@ast

Whole-exome sequencing identif ...... rminant in lower-grade glioma.

@en

Whole-exome sequencing identif ...... rminant in lower-grade glioma.

@nl

type

label

Whole-exome sequencing identif ...... rminant in lower-grade glioma.

@ast

Whole-exome sequencing identif ...... rminant in lower-grade glioma.

@en

Whole-exome sequencing identif ...... rminant in lower-grade glioma.

@nl

prefLabel

Whole-exome sequencing identif ...... rminant in lower-grade glioma.

@ast

Whole-exome sequencing identif ...... rminant in lower-grade glioma.

@en

Whole-exome sequencing identif ...... rminant in lower-grade glioma.

@nl

P1433

Q34308674-47E58194-75FE-403F-989D-C9252C2FDB32

P1476

Q34308674-96E2B9EC-0E24-4B5F-8A91-1434CF3E6EBA

P2093

Q34308674-07A83DF2-F9C0-46CF-8F56-7F5DA9A510B7

Q34308674-3D71D635-693C-4C36-9E0E-A291275B8870

Q34308674-5109462E-1A64-4A52-8204-E1804FBA19EF

Q34308674-8E1E50E0-79C4-43AC-B714-457A3FD1555A

Q34308674-92D08151-7865-4719-96AC-5832E7414D2C

Q34308674-AFEBC624-B4DA-43BD-823A-35A9E566AC88

Q34308674-D9048E4B-76AB-4A9B-A273-1BE6D808A8B4

Q34308674-EA3D9211-93FD-4973-94F8-D5E05EF8F90D

Q34308674-F478AAB8-0DED-45F3-8F4E-EEE4191A2A43

Q34308674-FF5C3478-EAE3-4C75-83EF-72E4FE33C8BB

P2860

Q34308674-0190CDD1-7C33-40E4-9723-ED2F5518CC00

Q34308674-03877544-B011-4F33-A637-C87843895493

Q34308674-0A048ACC-848B-482B-9D8A-BEF449D21E2C

Q34308674-1A8C6058-3377-42D6-9437-2D13DA1928CF

Q34308674-1E1A0123-20F0-4B43-98D8-E878A9DE6571

Q34308674-1EFE32BE-52C5-4CE6-BD93-70E03FFFA053

Q34308674-2250D337-9952-4B80-8F34-BA9D9B8916E3

Q34308674-26BD95DB-2037-4DE4-9922-4C02EE96632D

Q34308674-4BBE5F71-22A7-4C10-9239-554321249A89

Q34308674-608D9EAD-B7EC-4F08-9232-2963BE89F69C

P304

Q34308674-2E32F8D1-4AD0-486F-B6D8-833C84EF85D2

P31

Q34308674-E6988544-7197-4A22-8CE9-B0230F4D244E

P356

Q34308674-82BF71CA-37A6-417F-85B3-5903C8F075A9

P407

Q34308674-22B0E1F0-BC0C-4901-8269-8154E327B594

P433

Q34308674-644A14AF-E6ED-4C0F-9E55-489F769B3949

P478

Q34308674-490873D7-662A-4F36-B088-CF492D8A9A50

P577

Q34308674-40EA3DB7-0E8E-4C7F-80C7-4B79FA1874BF

P5875

Q34308674-7951DFDD-53B8-4A86-B6A4-26155BDB3658

P698

Q34308674-6D9A34A5-53DA-410A-B0D1-BE8BEA6C5BB2

P932

Q34308674-C7803F79-D310-4DDB-B674-05C3FEA55C91

P356

P1433

P1476

Whole-exome sequencing identif ...... rminant in lower-grade glioma.

@en

P2093

Adriana Heguy

http://www.w3.org/2001/XMLSchema#string

Akiko Inagaki

http://www.w3.org/2001/XMLSchema#string

Daniel Gorovets

http://www.w3.org/2001/XMLSchema#string

Edward R Kastenhuber

http://www.w3.org/2001/XMLSchema#string

Jason T Huse

http://www.w3.org/2001/XMLSchema#string

Jianan Zhang

http://www.w3.org/2001/XMLSchema#string

Joachim Silber

http://www.w3.org/2001/XMLSchema#string

John H Petrini

http://www.w3.org/2001/XMLSchema#string

Kasthuri Kannan

http://www.w3.org/2001/XMLSchema#string

Timothy A Chan

http://www.w3.org/2001/XMLSchema#string

P2860

Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas

An integrated genomic analysis of human glioblastoma multiforme

IDH1 and IDH2 mutations in gliomas

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

P304

1194-1203

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.689

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232721312

http://www.w3.org/2001/XMLSchema#string

P698

23104868

http://www.w3.org/2001/XMLSchema#string

P932

3717947

http://www.w3.org/2001/XMLSchema#string